NANOSTICS TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO Disruptive Diagnostic Technology to Revolutionize Personalized Medicine

Nanostics Inc. (CNW Group/Nanostics)



Disruptive Diagnostic Technology to Revolutionize Personalized Medicine

Edmonton/Jan 9, 2020–Nanostics, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.

CEO John Lewis will be presenting Nanostics at Biotech Showcase as follows:

Date: Monday, January 13, 2020Time: 4:45 pm(PST)Room: Franciscan C, Level Ballroom

Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

Nanostics Inc., a company developing a novel liquid biopsy platform for the early diagnosis of clinically significant prostate cancer, is pleased to outline the ongoing clinical validation studywith ClarityDX Prostate. Currently, over 200 men with elevated PSA (the standard prostate cancer screen test) have been tested, out of the projected study total of2,800 men. This clinicalvalidation study is part of the process towards meeting FDA and Health Canada requirements for an in vitro diagnostic test, which will allow Nanostics proprietary ClarityDX Prostate test to be provided to patients.

Patient recruitment, managed by the Alberta Prostate Cancer Research Initiative (APCaRI), is occurring in Canada (Alberta and the Yukon) and the United States (Florida).The ClarityDX Prostate test is being used to analyze the samples in partnershipwithDynaLIFE Medical Labs.

Previously, a 415-patient prospective clinical study determined this novel liquid biopsy platformto be 40% more specific thanPSA. Nanostics also completed an intensive 2,000 sample stability study with the liquid biopsy blood test to determine optimal collection andtransportation conditions.

Funding for the clinical study comes in part from the Bird Dogs, Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.Recently, Nanostics initiated a Series A funding round to continue the development of ClarityDX Prostate and translation of this test to the clinic as an early diagnostic blood test for prostate cancer in men with elevated PSA.

The potential impact of the ClarityDX Prostate test is considerable; implementation could eliminate up to 600,000 unnecessary biopsies, 24,000 hospitalizations and up to 50% of unnecessary treatments for prostate cancer in North America. Beyond an estimated cost savings to the healthcare system of more than $1.4B per year, this will have a dramatic impact on the healthcare experience and quality of life for men.

“We are extremely excited to be clinically validating the ClarityDX Prostate test”, John Lewis, CEO of Nanostics said, “and we are grateful to all the support we have received in Alberta to make this possible.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for 2executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Nanostics will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASEBiotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives inone place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT NANOSTICS INC.Nanostics is a privately held company focused on the development and commercialization of novel and non-invasive diagnostic tests. Our core technology can diagnose disease from a simple blood test by combining a highly sensitive extracellular vesicle (EV) detection platform with advanced machine learning algorithms. Our novel technology is applicable to a wide range of cancers and other diseases. Our lead product,ClarityDX Prostate, is set to become the first clinically validated test using this exciting new EV detection technology.